Pfizer said Tuesday it signed a licensing agreement to allow broader global access to its experimental COVID-19 pill. The agreement with the Medicines Patent Pool, a United Nations-backed public ...

Pfizer reported lower third-quarter profit as demand for its Covid-19 vaccine and antiviral drug continued to decline.

NEW YORK -- When Laura Martin tested positive for COVID-19 last month during an extended stay in California, she was prescribed Paxlovid, the highly touted antiviral drug created by Pfizer. Just one ...

CHICAGO -- Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release. The study will ...

And despite the sales slump in the U.S. this past quarter, Pfizer’s Prevnar dynasty still leads in pediatric pneumococcal vaccination worldwide and among conjugated pneumococcal vaccines for adults in ...

Pfizer raised its full-year profit forecast for the second consecutive quarter and reported a higher-than-expected ...

Pfizer (PFE) stock is in focus as the company exceeds Street forecasts with its Q3 2025 results thanks mainly to its COVID ...

Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the ...

NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...

President Donald Trump today, Sept. 30, announced TrumpRX, a new website for Americans to buy drugs, while he touted lower prices across Pfizer drugs, according to the Wall Street Journal. Trump ...